Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Cigna (CI) Q4 Earnings And Revenues Beat Estimates, Rise Y/Y

Published 02/05/2020, 10:36 PM
Updated 07/09/2023, 06:31 AM

Cigna Corp. (NYSE:CI) came up with adjusted earnings of $4.54 per share in fourth-quarter 2019, surpassing the Zacks Consensus Estimate by 2.9%. Quarterly earnings were up 75% year over year.

Cigna’s revenues of $36.6 billion beat the Zacks Consensus Estimate by 3.7%. Revenues grew 167% year over year owing to the acquisition of Express Scripts (NASDAQ:ESRX).

Among the revenue components, pharmacy revenues were $25.6 billion compared with $3.3 billion in the year-ago quarter, premiums were up 9.8% year over year to $10 billion while fees increased 50.2% to $2.2 billion. The growth in pharmacy revenues was backed by the acquisition of pharmacy benefit manager Express Scripts.

The company’s medical enrollment grew by 184,000 lives from the prior-year quarter to 17.15 million customers, driven by growth in Commercial and International markets.

Cigna Corporation Price, Consensus and EPS Surprise

Segment Details

Health Services – Adjusted revenues of $25.6 billion were up from $3.3 billion in the year-ago quarter, primarily due to the acquisition of Express Scripts completed in December 2018.

Integrated Medical – Adjusted revenues of $9.2 billion were up 11% year over year, driven by increase in Commercial customer as well as premium growth.

International Markets – Adjusted revenues of $1.43 billion were up 5.5% year over year, reflecting continued business growth.

Capital Position

Cigna’s debt-to-capitalization ratio improved to 45.2% as on Dec 31, 2019, from 50.9% as of Dec 31, 2018.

Shareholders’ equity as of Dec 31, 2019 was $45.3 billion, up 10.5% year over year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

2020 Guidance

The company expects earnings per share in the range of $18-$18.6; adjusted revenues in the range of $154 billion to $156 billion. Medical customers are projected to grow between 150,000 and 250,000.
Medical care ratio is expected in the range of 80.2-81.2%.

Cigna carries a Zacks Rank #2 (Buy).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Some other stocks in the healthcare space that have reported fourth-quarter earnings so far, UnitedHealth Group Inc. (NYSE:UNH) and Humana Inc. (NYSE:HUM) beat earnings estimates by 3.45% and 3.64%, respectively, while Centene Corp. (NYSE:CNC) missed the same by 1.4%.

"More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

"



Cigna Corporation (CI): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.